NewLink Genetics (NLNK) Reaches New 12-Month Low at $1.80

Shares of NewLink Genetics Corp (NASDAQ:NLNK) reached a new 52-week low during trading on Tuesday . The company traded as low as $1.80 and last traded at $1.87, with a volume of 1041 shares traded. The stock had previously closed at $1.88.

NLNK has been the topic of a number of recent analyst reports. Stifel Nicolaus downgraded shares of NewLink Genetics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $8.00 to $4.00 in a research report on Wednesday, August 1st. Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Saturday, August 4th. Finally, Bank of America dropped their price target on shares of NewLink Genetics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, November 2nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $4.75.

The company has a market capitalization of $69.98 million, a PE ratio of -0.81 and a beta of 1.55.

NewLink Genetics (NASDAQ:NLNK) last announced its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.22. The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $2.10 million. NewLink Genetics had a negative net margin of 253.52% and a negative return on equity of 42.27%. Equities analysts forecast that NewLink Genetics Corp will post -1.48 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of NewLink Genetics by 0.8% in the 2nd quarter. BlackRock Inc. now owns 2,279,452 shares of the biotechnology company’s stock worth $10,850,000 after purchasing an additional 18,461 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of NewLink Genetics by 229.8% in the 3rd quarter. Renaissance Technologies LLC now owns 1,335,981 shares of the biotechnology company’s stock worth $3,193,000 after purchasing an additional 930,881 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of NewLink Genetics by 148.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,156,871 shares of the biotechnology company’s stock worth $2,765,000 after purchasing an additional 691,651 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of NewLink Genetics by 20.5% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 673,885 shares of the biotechnology company’s stock worth $3,208,000 after purchasing an additional 114,650 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its stake in shares of NewLink Genetics by 54.5% in the 3rd quarter. Panagora Asset Management Inc. now owns 577,262 shares of the biotechnology company’s stock worth $1,380,000 after purchasing an additional 203,617 shares during the last quarter. 44.87% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “NewLink Genetics (NLNK) Reaches New 12-Month Low at $1.80” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.chaffeybreeze.com/2018/11/21/newlink-genetics-nlnk-reaches-new-12-month-low-at-1-80.html.

About NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Further Reading: Understanding Market Liquidity

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply